Close navigation

Child brain tumour research projects

Although they're relatively rare, brain tumours are the biggest cancer killer of children and teenagers and the biggest cause of potentially treatable blindness in children - 62% of children who survive a brain tumour will be left with a life-altering, long-term disability.

Research is essential if we are to enhance our understanding of why and how each tumour forms, and what can be done to treat them.

This is why we fund research into a wide variety of childhood brain tumour types.

Current high grade brain tumour research projects

Here are the research projects we are currently funding that relate to understanding or treating high grade brain tumours in children

Dr Darren Hargrave

Tumour-targeted drugs for kids with diffuse midline glioma (aka DIPG)

share this

Dr Darren Hargrave

Tumour-targeted drugs for kids with diffuse midline glioma (aka DIPG)

We’re funding the UK participation of BIOMEDE, an international, adaptive clinical trial for children with Diffuse Midline Gliomas - pontine location (DMG, formerly known as DIPG). The trial is the first of its kind because it requires the children to have a biopsy of the tumour, and based on the molecular traits of the tumour different treatments are assigned.

The adaptive nature of this trial means that as new treatments become available for this kind of tumour, they can be added into the trial. This is key so that children get access to the new, potentially life-saving treatments faster.

Find out more

share this

Dr Adrian Bracken

Finding new methods to treat Diffuse Midline Glioma

share this

Dr Adrian Bracken

Finding new methods to treat Diffuse Midline Glioma

Dr Adrian Bracken and his research team at Trinity College Dublin aim to develop new methods to treat diffuse midline glioma, formerly known as Diffuse Intrinsic Pontine Glioma (DIPG).

Previous research has demonstrated that the regulation of chromatin is disrupted in various cancers. Chromatin regulation refers to the process of DNA being wrapped around special proteins called histones. The research team will be focusing on finding new ways to block the activity of a particular protein involved in chromatin deregulation.

Find out more

share this

Prof. Steve Clifford

INSTINCT:on a mission to beat childhood brain tumours

share this

Professor Steve Clifford

INSTINCT:on a mission to beat childhood brain tumours

Our INSTINCT programme brings together experts from Newcastle University, the Institute of Cancer Research (ICR) and the UCL Institute for Child Health in London to research high-risk childhood brain tumours, including DIPG.

The research programme on DIPG is being led by Dr Chris Jones at the Institute of Cancer Research. Dr Jones has extensive experience in understanding the genetic basis of these tumours and what is driving tumour growth and then developing new drugs that target the genes involved. 

Find out more

share this

Prof. Colin Watts

Tessa Jowell BRAIN MATRIX

share this

Professor Colin Watts

Tessa Jowell BRAIN MATRIX

The Tessa Jowell BRAIN-MATRIX is a first-of-its-kind clinical trial that will enable doctors to treat brain tumours with drugs that are more targeted than ever before. We are excited to be investing £2.8 million to set the trial up, and to drive it into the future.

Although the trial is being led from the UK, we expect it to deliver global impact for brain cancer patients.

Find out more

share this

Prof. Colin Kennedy

The PROMOTE Study

share this

Professor Colin Kennedy

The PROMOTE Study

The project is named The PROMOTE Study - Patient Reported Outcome Measures Online To Enhance Communication and Quality of Life after childhood brain tumour.

The PROMOTE team are developing an online programme called KLIK which will be used by children and their families to keep track of any issues they have between consultations.

This research will propel our ability to understand, and potentially prevent, the harsh side effects of brain tumour treatment in children to help accelerate a change for those affected.

Find out more

share this

Dr Paul Northcott

Medulloblastoma Epigenome Regulation in Treatment (MERIT)

share this

Dr Paul Northcott

Medulloblastoma Epigenome Regulation in Treatment (MERIT)

Previous research has shown that epigenetic changes contribute to treatment resistance in medulloblastomas. Epigenetic changes refer to changes in the structure of DNA that alter the way DNA is 'read' by the cell. The aim of this research programme, led by Dr Paul Northcott, is to identify the epigenetic changes occurring in Group 3 medulloblastomas in response to treatment.

Find out more

share this

Prof. Terrance Johns

Preventing resistance to targeted therapies

share this

Professor Terrance Johns

Preventing resistance to targeted therapies

Despite aggressive treatment with surgery, radiotherapy and chemotherapy, patients with HGGs have an extremely poor prognosis.

A number of targeted therapies have also been tested but have failed to improve outcomes for these patients, highlighting the urgent need to better understand the biology of these tumours and why treatments fail.

This research aims to identify new drug combinations that are more effective and may improve survival for patients with HGGs. And by using treatments that are already approved and used in clinical practice, this process will be dramatically sped up.

Find out more

share this

Dr Laure Bihannic

Understanding the origins of medulloblastoma

share this

Dr Laure Bihannic

Understanding the origins of medulloblastoma

To create effective preclinical tumour models, it is imperative to know the cells from which the tumours originate. While it is known which cells WNT and SHH medulloblastomas arise from, the cellular origins of Groups 3 and 4 remain unknown. The aim of this research project, led by Dr Laure Bihannic, is to understand which cells give rise to Groups 3 and 4 medulloblastomas and use this knowledge to create accurate preclinical models for these subgroups.

Find out more

share this

Prof. Steve Clifford

PNET5 trial: transforming treatments for childhood brain tumours

share this

Professor Steve Clifford

PNET5 trial: transforming treatments for childhood brain tumours

Medulloblastomas are the most common high grade brain tumours in children. The standard treatment for this tumour type is removing the tumour with surgery, followed with chemotherapy and radiotherapy.

However, these treatments are quite aggressive and cause long-term, life-altering disabilities. The PNET5 clinical trial aims to improve the quality of survival of these children by providing kinder and tailored treatments.

Find out more

share this

Prof. Chris Clark

Taking a closer look at brain injury

share this

Professor Chris Clark

Taking a closer look at brain injury

Treatment for children with medulloblastoma, an aggressive type of brain tumour, is frequently accompanied by damage to the brain with long-term implications such as memory loss.

His research focus is on the development and application of imaging for the understanding of neurological disability. The development of these methods will lead to better neurosurgical planning in both children and adults.

Find out more

share this

Dr Paul Northcott

Understanding the significance of medulloblastoma subtypes

share this

Dr Paul Northcott

Understanding the significance of medulloblastoma subtypes

The 2016 revision of brain tumour classifications from the World Health Organisation (WHO) included the four consensus subgroups for medulloblastoma (WNT-activated, SHH-activated, Group 3 and Group 4).

To date, medulloblastomas in Groups 3 and 4 have been notoriously difficult to treat because they have many different and unpredictable responses to treatment.

Dr Northcott’s team will use sophisticated statistical analysis, on over 1,200 samples, to determine if there are further subtypes within these subgroups.

Find out more

share this

Prof. Louis Chesler

New drug development for medulloblastoma

share this

Professor Louis Chesler

New drug development for medulloblastoma

Professor Chesler is working with a team from Germany and the USA to study Group 3 medulloblastoma. The team will be analysing the genome in medulloblastoma tumour cells while also working on new ways to test drugs for this tumour type.

If successful, the research could, for the first time, reveal how these tumours are wired. This could mean that new drugs to treat this tumour type are delivered to the clinic within five years.

Find out more

share this

Prof. Colin Kennedy

Quality of survival in a Europe-wide clinical trial

share this

Professor Colin Kennedy

Quality of survival in a Europe-wide clinical trial

This funding supports the quality of survival aspects of the European clinical trial entitled SIOP-PNET5-MB. This trial is for children with medulloblastoma tumours that have been defined in the clinic as "standard risk". The purpose of the trial is to assess whether treatment can be reduced so that these children experience less long term side effects, but still benefit from the anti-tumour activity of the protocol.

Find out more

share this

Mr Conor Mallucci

Solving the mystery behind Cerebellar Mutism Syndrome

share this

Mr Conor Mallucci

Solving the mystery behind Cerebellar Mutism Syndrome

Mr Mallucci will be carrying out a multi-centre study to investigate Cerebellar Mutism Syndrome (CMS), a.k.a. Posterior Fossa Syndrome, a serious and poorly understood late effect resulting from surgical complication. It is seen in up to 25% of children after removing tumours from the very back of the skull, known as the cerebellum.

Find out more

share this

Dr Lee Wong

Investigating tumour initiating events

share this

Dr Lee Wong

Investigating tumour initiating events

Previous research has demonstrated that chromatin regulation is often disrupted in many cancers. Mutations, or changes, in histone proteins leads to the initiation of many cancers, including gliomas.

The aim of the research, led by Dr Wong, is to understand the role of a specific histone protein, called H3.3, and how changes in this protein drive tumour growth.

Survival rates for individuals diagnosed with gliomas depend on a host of factors, but only 19% of adults diagnosed with a brain tumour survive for five years after their diagnosis. So it’s important that further research is done to inform our understanding of how and why these tumours start.

Find out more

share this

Professor Richard Gilbertson

No brain tumour ignored

share this

Professor Richard Gilbertson

No brain tumour ignored

This grant is for a large programme of work into two different rare childhood brain tumours. Professor Gilbertson will focus on three main areas of work: making better models to use in the lab, discovering and testing new drugs, and trialling the best way to deliver new drugs to tumours.

Find out more

share this

Dr Sophie Thomas

Rebuilding a meaningful life for young people

share this

Dr Sophie Thomas

Rebuilding a meaningful life for young people

Acceptance and Commitment Therapy (ACT) is a psychological intervention with a broad focus. Dr Sophie Thomas aims to assess the feasibility and acceptability of ACT to help young people, aged 11-24 years, who have survived a childhood brain tumour.

Find out more

share this

Professor Michael Hawkins

Improving Survival for Survivors

share this

Professor Michael Hawkins

Improving Survival for Survivors

This research project, led by Professor Hawkins, aims to establish one system that would allow us to monitor the health outcomes of brain tumour survivors under the age of 40. This system would help us track the risks associated with surviving a brain tumour and then help us to identify groups of survivors that have increased risk of poor health outcomes.

Find out more

share this

Dr Jan Schuemann

Extreme dose rate proton therapy

share this

Dr Jan Schuemann

Extreme dose rate proton therapy

Previous studies have shown that delivering radiotherapy extremely rapidly can dramatically reduce side-effects. Radiation therapy that delivers the same dose of radiation in a much shorter period of time is called extreme dose radiation (EDR). EDR therapy has not been tested using proton beams, and that’s where this innovative research project comes in.

The research team, led by Dr Schuemann, will use pre-clinical models to test EDR proton therapy with the aim of establishing a treatment regimen that’s effective and well-tolerated by people. They’ll compare EDR to conventional radiation delivery and look for any differences in side-effects, specifically looking into the effects on cognition and motor control.

Learn more

share this

Current low grade brain tumour research projects

Here are the research projects we are currently funding that relate to understanding or treating low grade brain tumours in children

Prof. Colin Watts

Tessa Jowell BRAIN MATRIX

share this

Professor Colin Watts

Tessa Jowell BRAIN MATRIX

The Tessa Jowell BRAIN-MATRIX is a first-of-its-kind clinical trial that will enable doctors to treat brain tumours with drugs that are more targeted than ever before. We are excited to be investing £2.8 million to set the trial up, and to drive it into the future.

Although the trial is being led from the UK, we expect it to deliver global impact for brain cancer patients.

Find out more

share this

Prof. Colin Kennedy

The PROMOTE Study

share this

Professor Colin Kennedy

The PROMOTE Study

The project is named The PROMOTE Study - Patient Reported Outcome Measures Online To Enhance Communication and Quality of Life after childhood brain tumour.

The PROMOTE team are developing an online programme called KLIK which will be used by children and their families to keep track of any issues they have between consultations.

This research will propel our ability to understand, and potentially prevent, the harsh side effects of brain tumour treatment in children to help accelerate a change for those affected.

Find out more

share this

Dr David Jones

The Everest Centre

share this

Dr David Jones

The Everest Centre

The Everest Centre is being financed by The Brain Tumour Charity with money raised by the family and friends of Toby Ritchie, who was diagnosed with a low grade brain tumour at the age of five. 

The centre will fund several, vital research projects that will help us understand more about low grade paediatric brain tumours and trial new treatments.

Find out more

share this

Prof. Denise Sheer & Prof. JP Martinez-Barbera

Making models of paediatric low grade glioma

share this

Professor Denise Sheer & Professor JP Martinez-Barbera

Making models of paediatric low grade glioma

The team are working to create pre-clinical models for childhood low grade brain tumours (glioma).

Pre-clinical models are used by scientists to test new treatments in the lab before they are then used in humans, as part of a clinical trial.

Once we know the models work correctly, we can understand how the tumour can be treated and defeated. Low grade gliomas currently account for half of children with brain tumours, so this will be a significant advance.

Find out more

share this

Dr Susan Picton

Testing a new drug combination for young people with low grade brain tumours

share this

Dr Susan Picton

Testing a new drug combination for young people with low grade brain tumours

Dr Susan Picton and colleagues at the University of Leeds and Birmingham Clinical Trials Unit are conducting a clinical trial to determine the potential value and best dose when combining the drugs nilotinib and vinblastine to treat young people with brain tumours.

The researchers are focusing on low grade childhood brain tumours called gliomas. Gliomas are often inoperable because of their location and can become more aggressive over time.

Find out more

share this

Dr Todd Hankinson

Identifying directed therapies for Adamantinomatous Craniopharyngioma (ACP)

share this

Dr Todd Hankinson

Identifying directed therapies for Adamantinomatous Craniopharyngioma (ACP)

Almost all children with ACP suffer from a life-altering side effect or injury from either the tumour itself or treatment. Side effects and injuries include hormone imbalances, blindness, and morbid obesity. The current standard of treatment includes surgical removal of the tumour followed by radiation therapy – there are currently no targeted therapies to treat ACP.

The aim of the research programme, led by Dr Todd Hankinson, is to understand the behaviour of the different types of cells and identify targets for treatment.

Find out more

share this

Dr Lee Wong

Investigating tumour initiating events

share this

Dr Lee Wong

Investigating tumour initiating events

Previous research has demonstrated that chromatin regulation is often disrupted in many cancers. Mutations, or changes, in histone proteins leads to the initiation of many cancers, including gliomas.

The aim of the research, led by Dr Wong, is to understand the role of a specific histone protein, called H3.3, and how changes in this protein drive tumour growth.

Survival rates for individuals diagnosed with gliomas depend on a host of factors, but only 19% of adults diagnosed with a brain tumour survive for five years after their diagnosis. So it’s important that further research is done to inform our understanding of how and why these tumours start.

Find out more

share this

Dr Sophie Thomas

ACT for young people

share this

Dr Sophie Thomas

ACT NOW (Acceptance and Commitment Therapy for Neuro-Oncology Wellness

Find out more

share this

Prof. Michael Hawkins

Combining data for better monitoring

share this

Professor Michael Hawkins

Combining data for better monitoring

Find out more

share this

Dr Jan Schuemann

Extreme dose rate proton therapy

share this

Dr Jan Schuemann

Extreme dose rate proton therapy

Previous studies have shown that delivering radiotherapy extremely rapidly can dramatically reduce side-effects. Radiation therapy that delivers the same dose of radiation in a much shorter period of time is called extreme dose radiation (EDR). EDR therapy has not been tested using proton beams, and that’s where this innovative research project comes in.

The research team, led by Dr Schuemann, will use pre-clinical models to test EDR proton therapy with the aim of establishing a treatment regimen that’s effective and well-tolerated by people. They’ll compare EDR to conventional radiation delivery and look for any differences in side-effects, specifically looking into the effects on cognition and motor control.

Learn more

share this

Newly diagnosed with a brain tumour Created with Sketch. Diagnosed? newly

Our free Brainy Bag contains toys and activities to help parents and carers create a relaxed environment with their child to address some difficult emotions they may be feeling about their diagnosis.